These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18210304)

  • 21. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
    Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
    Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developing drugs that do not cause tumor regression.
    Stadler W
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
    [No Abstract]   [Full Text] [Related]  

  • 23. Dodging a dogma: is treating beyond progression beneficial?
    Naing A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 May; 71(5):1385-6. PubMed ID: 23443308
    [No Abstract]   [Full Text] [Related]  

  • 24. Mathematical models in high-dose chemotherapy.
    Souhami RL; Gregory WM; Birkhead BG
    Antibiot Chemother (1971); 1988; 41():21-8. PubMed ID: 3245689
    [No Abstract]   [Full Text] [Related]  

  • 25. Tetrofosmin as predictors of tumour response.
    Fuster D; Viñolas N; Mallafré C; Pavia J; Martín F; Pons F
    Q J Nucl Med; 2003 Mar; 47(1):58-62. PubMed ID: 12714956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer therapy: could a novel test predict the amount of drug that reaches its target?
    van der Veldt AA; Smit EF; Lammertsma AA
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):377-9. PubMed ID: 23560831
    [No Abstract]   [Full Text] [Related]  

  • 27. Tumour response, correlates of survival and clinical benefit.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Aug; 12(8):433. PubMed ID: 26220355
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-tumor activity of immunomodulatory peptide alloferon-1 in mouse tumor transplantation model.
    Chernysh S; Irina K; Irina A
    Int Immunopharmacol; 2012 Jan; 12(1):312-4. PubMed ID: 22051974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is tumor response important for renal carcinoma?
    Inman BA; George DJ
    Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245
    [No Abstract]   [Full Text] [Related]  

  • 30. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 31. From the guest editor: monitoring of therapeutic response to cancer treatment.
    Fojo T
    Cancer J; 2009; 15(5):352-3. PubMed ID: 19826352
    [No Abstract]   [Full Text] [Related]  

  • 32. Assessment of tumor response in malignant pleural mesothelioma.
    Ceresoli GL; Chiti A; Zucali PA; Cappuzzo F; De Vincenzo F; Cavina R; Rodari M; Poretti D; Lutman FR; Santoro A
    Cancer Treat Rev; 2007 Oct; 33(6):533-41. PubMed ID: 17764849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of targeted mouse models for preclinical testing of novel cancer therapeutics.
    Olive KP; Tuveson DA
    Clin Cancer Res; 2006 Sep; 12(18):5277-87. PubMed ID: 17000660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Research outcomes and recommendations for the assessment of progression in cancer clinical trials.
    Bushnell W; Stone A
    J Biopharm Stat; 2013; 23(5):949-50. PubMed ID: 23957508
    [No Abstract]   [Full Text] [Related]  

  • 35. Optimal lesion number for evaluation of tumor response in response evaluation criteria in solid tumors.
    Rosen MA; Sullivan D
    J Clin Oncol; 2010 Apr; 28(10):e159-60; author reply e161. PubMed ID: 20159810
    [No Abstract]   [Full Text] [Related]  

  • 36. Tumor response evaluation in oncology: current update.
    Shanbhogue AK; Karnad AB; Prasad SR
    J Comput Assist Tomogr; 2010 Jul; 34(4):479-84. PubMed ID: 20657213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 38. Mathematical modeling of cancer progression and response to chemotherapy.
    Sanga S; Sinek JP; Frieboes HB; Ferrari M; Fruehauf JP; Cristini V
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1361-76. PubMed ID: 17069522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
    Joensuu H
    Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 'pre-induction course' with non-cross-reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia.
    Daenen S; van Imhoff GW; de Wolf JT; Vellenga E; van den Berg-de Ruiter E; Kluin-Nelemans HC
    Br J Haematol; 2007 Jul; 138(2):275-7. PubMed ID: 17593034
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.